MD Anderson Cancer

Houston, Texas 77030

1 studies enrolling now · 3 studies all time

What they study most

Blinatumomab, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin's Lymphoma, KMT2A-rearranged, Lymphoblastic Leukemia, Mantle Cell Lymphoma, Melanoma, Revumenib

Studies at this site

• A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia — Starting soon
• Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia — Completed
• Safety of TKI258 in Advanced/Metastatic Melanoma Subjects — Completed